Department of Rehabilitation Medicine, Emory University, 1441 Clifton Road NE, Suite 150, Atlanta, GA 30322, USA.
J Neurooncol. 2010 Jan;96(2):271-6. doi: 10.1007/s11060-009-9960-y. Epub 2009 Jul 19.
Neuropsychological tests are increasingly being used as outcome measures in clinical trials of brain tumor therapies. This study informs development of brief neurocognitive batteries for clinical trials by identifying cognitive tasks that detect effects on a group level in a mixed brain tumor population. This is a retrospective study of brain tumor patients who completed a standardized battery sampling multiple cognitive domains using twelve subtests with widely-used task formats (the Repeatable Battery for the Assessment of Neuropsychological Status). Sixty-eight patients with brain tumors were studied (60% high-grade glioma). Forty patients (58.8%) were impaired (>2 standard deviations below published means) on at least one subtest. A combination of four subtests (Figure Copy, Coding, List Recognition, and Story Recall) captured 90% of the impaired subgroup. These results suggest visuoconstruction, processing speed, and verbal memory measures may be the most important domains to assess when evaluating cognitive change in brain tumor clinical trials.
神经心理学测试越来越多地被用作脑肿瘤治疗临床试验的结果衡量标准。本研究通过确定在混合脑肿瘤人群中在组水平上检测到效果的认知任务，为临床试验提供了简短的神经认知电池的开发信息。这是一项对脑肿瘤患者的回顾性研究，他们使用十二项具有广泛使用任务格式的子测试（用于认知状态评估的可重复电池）完成了一个标准化电池采样，涵盖了多个认知领域。共有 68 名脑肿瘤患者（60%为高级别胶质瘤）参与了研究。40 名患者（58.8%）在至少一项子测试中受损（低于发表平均值 2 个标准差以上）。四项子测试（图复制、编码、列表识别和故事回忆）的组合涵盖了 90%的受损亚组。这些结果表明，在评估脑肿瘤临床试验中的认知变化时，视空间构建、加工速度和言语记忆测量可能是最重要的评估领域。
